Growth hormone treatment in children with Noonan's syndrome: four year results of a partly controlled trial.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

The aim of the study was to evaluate the effect of continuous and discontinuous growth hormone treatment in Noonan's syndrome (NS) on linear growth and bone maturation.

Why It Was Studied

Group A (n = 8) immediately started GH treatment and after 2 y discontinued GH treatment for 1 y; group B (n = 15) served as a control group during the first year and started GH treatment after 1 y.

After the 3 y study period, 17 out of the 23 children continued GH treatment.

Who Took Part

The abstract describes 23 children taking part.

PubMed indexes the participants as young children, children and teenagers, both men and women.

An additional 14 children (group C) were treated according to the same protocol, but without discontinuation of GH treatment.

The effect of GH treatment for up to 3 y was evaluated in terms of gain in height standard deviation score (H-SDS) for calendar age and for bone age.

How the Study Was Run

In design terms this was a randomized and multicenter study.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

Running at several centres spread the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study over different clinics and patient groups.

What Was Measured

Topics PubMed links to this paper include Analysis of Variance, Body Height, Growth Hormone and Noonan Syndrome.

What This Means in Plain Language

The paper is a randomized and multicenter study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 23 children.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 2 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2001 (Acta paediatrica (Oslo, Norway : 1992)), a journal based in Norway.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.